Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
about
Advances in antibiotic therapy in the critically illOptimizing antimicrobial therapy in critically ill patientsCommunity-acquired pneumonia: identification and evaluation of nonrespondersTherapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?Clinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot StudyMeropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?Clinical on-site monitoring of ß-lactam antibiotics for a personalized antibiotherapy.Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancyIndividualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic.Continuous infusion of piperacillin/tazobactam in septic critically ill patients--a multicenter propensity matched analysis.How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Continuous versus short-term infusion of cefuroxime: assessment of concept based on plasma, subcutaneous tissue, and bone pharmacokinetics in an animal model.Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patientsAntibiotics and extracorporeal circulation--one size does not fit allAssays for determination of ertapenem for applications in therapeutic drug monitoring, pharmacokinetics and sample stability.A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics.Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapyTherapeutic drug monitoring of antimicrobials.Measurement of ceftazidime concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Application to critically ill patients and patients with osteoarticular infections.Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?Case-control study of drug monitoring of β-lactams in obese critically ill patients.Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute InfectionsProtein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?Antibiotic dosing in critically ill patients with acute kidney injury.β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.Therapeutic drug monitoring for tomorrow.Approaches for dosage individualisation in critically ill patients.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis.Antibiotic resistance in cancer patients.Shortening the course of antibiotic treatment in the intensive care unit.Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with β-lactams: a systematic review and meta-analysis.Simultaneous determination of 12 beta-lactam antibiotics in human plasma by high-performance liquid chromatography with UV detection: application to therapeutic drug monitoring.
P2860
Q26749328-16DAD955-1690-49E2-9FB8-621A74DF5289Q26999905-19CB107F-F8F3-4DAD-8581-CD0DE93EDBD8Q27002420-4CCDB70B-3755-4F25-AAF2-197A5CE6EAB3Q28080607-F2979C14-D5DC-4D9E-916A-9D0055A40081Q28551453-FB009BFD-70A0-4B36-A721-9797AE90DF58Q33751132-1CD0C3DA-1BED-4A44-B8E9-897729A1EB54Q33784516-0F018396-3C7B-49F4-9EB3-BF451B7E7D50Q33797868-ACDDCDB0-36B0-4834-8741-51647968A5C1Q33798203-E969E0B8-3B6E-4872-8654-0E2CC22D9234Q33824276-30067B51-992D-492C-A61F-8282B5957869Q34274190-CCD817AF-E6F5-4202-8AA7-0579BDA4FC7FQ34329290-85060214-AB4B-463D-AE84-493C96DE2D6BQ34490565-BA85E33B-1F53-4732-8050-F3C31AA103B5Q34894900-3473EBAF-5745-4FB5-BC23-B70E94B0ED95Q34923002-DF27E33A-AF6A-4F08-AAFF-1C1E53CD7C9DQ35076958-A974836A-3508-40A9-86DF-725F1B430BA2Q35091940-2773B2B2-9512-4AE4-8664-F0DE75DB77DAQ35218071-CF574544-E808-427B-B9E4-471A42EB477DQ35504097-98591F19-6ADE-40D3-AFDD-187A0DBF01C8Q35558292-90044B2B-AD6E-4F32-A040-F19646790E83Q35640430-A3897BD4-DFE5-4318-8B92-8AD88E6CE7DEQ35694058-6BDC143D-AA15-4D0F-8C6E-5067771D4D53Q35827280-FEB71F69-006B-497C-B380-E6AF5C521524Q35908084-5BC12511-C5A4-466C-B9FC-43C12E5EE95BQ36158212-A1FD8077-87F1-47DD-BE5C-686944C6C736Q36287127-54F6F2E7-0A80-4CC1-9257-4E2F37BB8CDDQ36517624-19531BDD-629E-4CD8-86FF-7A73476DBDD7Q36558332-4CF684D7-27FA-47CE-B0A4-CDAB574F53B7Q37306664-B9C4AA5D-D714-42A4-98D9-CDEE6E6974EBQ37335840-AF1A4712-5495-483A-BE4D-1F37CFCB83D3Q37846092-F3941EC6-E116-4561-947D-EF5DD4D0A942Q38004063-7955AA04-4F94-400A-892F-F381BE79259DQ38103768-BFAC2BF6-8C3E-40A3-BD75-907EA89A5A09Q38125209-B0FC2C0D-6173-4684-8BD6-3C838865C898Q38138835-C006A834-0783-477C-8788-E911602E2596Q38167345-31C4BFF3-4F9B-454F-98BB-B91DE07A1EDDQ38212258-3CD0A526-361E-47A5-AFD4-E0615F489EE3Q38341882-F9460D73-2543-4C9B-98E1-2B61E4B48503Q38511551-5A5E9B5B-CD97-4161-9071-1C30FDFFAE66Q38627385-8E9248E4-1045-4195-ADE9-7F10AEAB31CB
P2860
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
@en
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
@nl
type
label
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
@en
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
@nl
prefLabel
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
@en
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
@nl
P50
P1476
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
@en
P2093
Brett McWhinney
Marta Ulldemolins
P304
P356
10.1016/J.IJANTIMICAG.2010.06.008
P577
2010-08-03T00:00:00Z